4.7 Review

Peptide-based delivery to bone

期刊

ADVANCED DRUG DELIVERY REVIEWS
卷 64, 期 12, 页码 1220-1238

出版社

ELSEVIER
DOI: 10.1016/j.addr.2012.05.017

关键词

RANKL (receptor activator of NF-kappa B ligand); Antagonist; Bone resorption inhibitory peptide; Bone formation stimulatory peptide; Cholesterol-bearing pullulan (CHP) nanogel; BMP; Collagen; Thrombin; Bone-targeting peptide; Half-life; Stability

资金

  1. Ministry of Education, Culture, Sports, Science, and Technology of Japan [19390472, 23659867, 22-00432]
  2. Grants-in-Aid for Scientific Research [24390413, 23659867] Funding Source: KAKEN

向作者/读者索取更多资源

Peptides are attractive as novel therapeutic reagents, since they are flexible in adopting and mimicking the local structural features of proteins. Versatile capabilities to perform organic synthetic manipulations are another unique feature of peptides compared to protein-based medicines, such as antibodies. On the other hand, a disadvantage of using a peptide for a therapeutic purpose is its low stability and/or high level of aggregation. During the past two decades, numerous peptides were developed for the treatment of bone diseases, and some peptides have already been used for local applications to repair bone defects in the clinic. However, very few peptides have the ability to form bone themselves. We herein summarize the effects of the therapeutic peptides on bone loss and/or local bone defects, including the results from basic studies. We also herein describe some possible methods for overcoming the obstacles associated with using therapeutic peptide candidates. (C) 2012 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据